EMA Authorised: Xarelto (rivaroxaban) — Bayer AG

View source ↗

Summary

The European Medicines Agency authorised Xarelto (rivaroxaban) for the prevention of venous thromboembolism in patients undergoing arthroplasty (replacement sur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Status: Authorised. Therapeutic area: Arthroplasty, Replacement;Venous Thromboembolism. MAH: Bayer AG. Decision date: 09/09/2024